Navigation Links
Perrigo Receives FDA Tentative Approval For Generic Equivalent To Prandin(R)
Date:7/19/2013

ALLEGAN, Mich., July 19, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received tentative approval from the U.S. Food & Drug Administration (FDA) for its abbreviated new drug application (ANDA) for repaglinide tablets, the generic equivalent to Prandin® Tablets (repaglinide tablets).

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

Prandin® tablets (repaglinide tablets), are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus and have annual sales of approximately $250 million, as measured by Symphony Health Solutions.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This approval shows the talent and expertise of our R&D and regulatory affairs departments. This is another example of Perrigo's commitment to bring new products to market and deliver on its mission to provide quality, affordable healthcare to consumers."

From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Company has grown to become a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico, the United Kingdom, India, China and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2012, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million
2. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
3. Perrigo Launches First-Ever Industry Marketing Campaign For Store Brand OTC Medications
4. Perrigo Reports Record Revenue and Adjusted Earnings
5. Perrigo Company To Release Third Quarter Fiscal Year 2013 Results On May 7, 2013
6. Perrigo Company To Present At The Barclays Global Healthcare Conference
7. Perrigo Company To Present At The RBC Global Healthcare Conference
8. Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%
9. Perrigo Company To Present At The Leerink Swann Global Healthcare Conference
10. Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million
11. Perrigo Confirms FDA Approval For Testosterone Gel 1%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 5, 2016  As people age, it is natural ... recommended screenings and tests that are linked with certain ... for the majority of aging individuals, hearing health is ... the 37.5 million American adults who report some trouble ... make hearing health a 2016 healthy aging priority.[1] ...
(Date:2/5/2016)... Aethlon Medical, Inc. (Nasdaq: AEMD ), today announced that ... at Source Capital Group,s 2016 Disruptive Growth & Healthcare Conference ... p.m. ET on Wednesday, February 10, 2016.  Mr. Joyce will ... 3:15 p.m. ET. http://www.aethlonmedical.com .  The webcast will ... of the live event. The panel discussion will not be ...
(Date:2/5/2016)... , Feb. 5, 2016  Zimmer Biomet Holdings, Inc. ... the previously announced underwritten secondary offering of 11,027,558 shares ... consisting of affiliates of Blackstone and Goldman Sachs.  The ... initial price of $96.45 per share. The selling stockholders ...  Neither Zimmer Biomet nor any of its directors, officers ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Steven Tonkinson, 36, of Coconut Grove, Florida, ... since it started in 2003. This year, he ran all 26.2 miles with a ... NBA team the Miami Heat. , This Sunday, while many are watching the Superbowl, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Successful ... for new clinical and scientific initiatives have all marked the last 12 months ... President and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Looking for ... may be at the tips of your toes. Foot massage, whether administered by a ... pure comfort and relaxation. The American Board of Multiple Specialties in Podiatry ...
(Date:2/5/2016)... ... 05, 2016 , ... US Sports Camps , official operators of Nike ... high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in the picturesque New ... ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled to be ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... to search for and donate to Give To Cure’s campaign that is crowdfunding clinical ... lets users make and share payments through a smart device. In 2015 alone, Venmo ...
Breaking Medicine News(10 mins):